Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.60 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929117 | 1.00 | PDGFRB (0.60) | PDGFRBLRRK2KDRTGM2PLK4 | |
| SCHEMBL275354 | 0.91 | LRRK2 (0.58) | PDGFRBLRRK2KDRPLK4PLK1 | |
| SCHEMBL275355 | 0.91 | LRRK2 (0.58) | PDGFRBLRRK2KDRPLK4PLK1 | |
| SCHEMBL279162 | 0.91 | LRRK2 (0.58) | PDGFRBLRRK2KDRPLK4PLK1 | |
| SCHEMBL14675079 | 0.90 | PDGFRB (0.64) | PDGFRBKDRTGM2PLK4PLK1 | |
| SCHEMBL14675080 | 0.90 | PDGFRB (0.64) | PDGFRBKDRTGM2PLK4PLK1 | |
| SCHEMBL4722687 | 0.89 | LRRK2 (0.67) | PDGFRBLRRK2KDRMDM2 | |
| SCHEMBL13929132 | 0.89 | LRRK2 (0.67) | PDGFRBLRRK2KDRMDM2 | |
| SCHEMBL29638270 | 0.89 | LRRK2 (0.67) | PDGFRBLRRK2KDRMDM2 | |
| SCHEMBL250592 | 0.89 | LRRK2 (0.65) | LRRK2PLK4PLK1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1996590-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-la Roche AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2007104664-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104664-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213341-A1 | Spiroindolinone derivatives | CHEN LI | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | RB1, PKD1, KRAS | PDGFRB 1273/4885LRRK2 234/4885KDR 260/4885 |
| US-20070213341-A1 | Spiroindolinone derivatives | MKI67, PKD1, RCC2 | PDGFRB 1596/4885LRRK2 1233/4885KDR 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.